Finally, we assessed the GVT activity of Ceacam1 2/2 donor alloreactive T cells against A20 lymphoma and RENCA renal cell carcinoma. Recipients of Ceacam1 2/2 donor T cells had improved survival in the A20 lymphoma model ( Figure 7A) , but both T cell replete groups showed comparable survival in the RENCA solid tumor model ( Figure 7B ). When we analyzed these two tumor lines for Ceacam1 expression, we noted that all A20 lymphoma cells uniformly expressed high levels, while only a subset of RENCA cells expressed some Ceacam1 ( Figure 7C ).